Literature DB >> 10027814

Endothelial function in Marfan syndrome: selective impairment of flow-mediated vasodilation.

D G Wilson1, M F Bellamy, M W Ramsey, J Goodfellow, M Brownlee, S Davies, J F Wilson, M J Lewis, A G Stuart.   

Abstract

BACKGROUND: The cardiovascular complications of Marfan syndrome arise due to alterations in the structural and functional properties of fibrillin, a constituent of vascular connective tissues. Fibrillin-containing microfibrils are closely associated with arterial endothelial cells, indicating a possible functional role for fibrillin in the endothelium. Plasma concentrations of endothelial cell products are elevated in Marfan subjects, which indirectly indicates endothelial dysfunction. This study directly assessed flow- and agonist-mediated endothelium-dependent brachial artery reactivity in Marfan subjects. METHODS AND
RESULTS: In 20 Marfan and 20 control subjects, brachial artery diameter, blood flow, and blood pressure were measured by ultrasonic wall tracking, Doppler ultrasound, and photoplethysmography, respectively. Measurements were taken during hand hyperemia (a stimulus for endothelium-derived nitric oxide [NO] release in the upstream brachial artery) and after sublingual administration of the endothelium-independent vasodilator nitroglycerin. In 9 Marfan and 6 control subjects, the above parameters were also assessed during intra-arterial infusions of acetylcholine and bradykinin (agonists that stimulate NO production) and NG-monomethyl-L-arginine (L-NMMA, an inhibitor of NO production). Flow-mediated responses differed markedly between Marfan and control subjects (-1.6+/-3.5% versus 6. 50+/-4.1%, respectively; P<0.0001), whereas nitroglycerin produced similar vasodilation (14.2+/-5.7% versus 15.2+/-7.8%; P=NS). Agonist-induced vasodilation to incremental intra-arterial infusions of acetylcholine and bradykinin were not significantly different between Marfan and control subjects, and intra-arterial L-NMMA produced similar reductions in brachial artery diameter in both groups.
CONCLUSIONS: These data demonstrate impaired flow-mediated but preserved agonist-mediated endothelium-dependent vasodilation in Marfan subjects and suggest preservation of basal NO release. Selective loss of flow-mediated dilation suggests a role for fibrillin in endothelial cell mechanotransduction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027814     DOI: 10.1161/01.cir.99.7.909

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  19 in total

1.  The prevalence and clinical impact of obesity in adults with Marfan syndrome.

Authors:  Anji T Yetman; Brian W McCrindle
Journal:  Can J Cardiol       Date:  2010-04       Impact factor: 5.223

2.  Sildenafil Prevents Marfan-Associated Emphysema and Early Pulmonary Artery Dilation in Mice.

Authors:  Zoe White; Nadia Milad; Arash Y Tehrani; Jennifer Lamothe; James C Hogg; Mitra Esfandiarei; Michael Seidman; Steven Booth; Tillie-Louise Hackett; Mathieu C Morissette; Pascal Bernatchez
Journal:  Am J Pathol       Date:  2019-05-22       Impact factor: 4.307

Review 3.  Marfan's syndrome and the heart.

Authors:  Alan Graham Stuart; Andrew Williams
Journal:  Arch Dis Child       Date:  2007-04       Impact factor: 3.791

4.  Impairment of flow-mediated dilation correlates with aortic dilation in patients with Marfan syndrome.

Authors:  Munenori Takata; Eisuke Amiya; Masafumi Watanabe; Kazuko Omori; Yasushi Imai; Daishi Fujita; Hiroshi Nishimura; Masayoshi Kato; Tetsuro Morota; Kan Nawata; Atsuko Ozeki; Aya Watanabe; Shuichi Kawarasaki; Yumiko Hosoya; Tomoko Nakao; Koji Maemura; Ryozo Nagai; Yasunobu Hirata; Issei Komuro
Journal:  Heart Vessels       Date:  2013-07-14       Impact factor: 2.037

5.  Endothelial dysfunction and compromised eNOS/Akt signaling in the thoracic aorta during the progression of Marfan syndrome.

Authors:  A W Y Chung; K Au Yeung; S F Cortes; G G S Sandor; D P Judge; H C Dietz; C van Breemen
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

6.  Fibrillin-1 genetic deficiency leads to pathological ageing of arteries in mice.

Authors:  Boubacar Mariko; Mylène Pezet; Brigitte Escoubet; Stéphanie Bouillot; Jean-Pierre Andrieu; Barry Starcher; Daniela Quaglino; Marie-Paule Jacob; Philippe Huber; Francesco Ramirez; Gilles Faury
Journal:  J Pathol       Date:  2011-03-22       Impact factor: 7.996

7.  Dysfunction of endothelial and smooth muscle cells in small arteries of a mouse model of Marfan syndrome.

Authors:  H T Syyong; A W Y Chung; H H C Yang; C van Breemen
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

8.  Cardiac remodeling in the mouse model of Marfan syndrome develops into two distinctive phenotypes.

Authors:  Hyun-Jin Tae; Natalia Petrashevskaya; Shannon Marshall; Melissa Krawczyk; Mark Talan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-11-13       Impact factor: 4.733

9.  Aortic Dimensions, Biophysical Properties, and Plasma Biomarkers in Children and Adults with Marfan or Loeys-Dietz Syndrome.

Authors:  Jason Z Cui; Kevin C Harris; Koen Raedschelders; Zsuzsanna Hollander; James E Potts; Astrid De Souza; Marla Kiess; Bruce M McManus; Pascal Bernatchez; Leslie A Raffin; Heidi Paine; Cornelis van Breemen; George G S Sandor; Mitra Esfandiarei
Journal:  CJC Open       Date:  2020-12-28

10.  Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse Model.

Authors:  Stijntje Hibender; Romy Franken; Cindy van Roomen; Anique Ter Braake; Ingeborg van der Made; Edith E Schermer; Quinn Gunst; Maurice J van den Hoff; Esther Lutgens; Yigal M Pinto; Maarten Groenink; Aeilko H Zwinderman; Barbara J M Mulder; Carlie J M de Vries; Vivian de Waard
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-06-09       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.